StevenM.KornblauMD

PubMed

• 99 citations
  Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia
  Sujan Piya, Steven M. Kornblau, Vivian Ruvolo, Hong Mu, Peter P. Ruvolo
  Blood. 2016-09-01
• 251 citations
  BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
  Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi, Nadeem A. Vellore, Johanna Estrada
  Cancer Cell. 2014-09-08
• 91 citations
  Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study
  Steven M. Kornblau, Deborah E. Banker, Derek L. Stirewalt, Danny D. Shen, Elizabeth Lemker
  Blood. 2005-11-16

Journal Articles

• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Nitin Jain, Courtney D. DiNardo, Steven Kornblau, Carlos Bueso-Ramos, Marina Konopleva, Hagop Kantarjian, Nature
• Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia  
  Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature

Abstracts/Posters

• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Proteomic Landscape of Acute Leukemia: A Comparison between ALL and AML in Adults
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Expression Profiling of mRNA By Next Generation Sequencing and the Development of Algorithm for Predicting Response in Acute Myeloid Leukemia
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Periphera...
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Trimethylated H3K27, and Di- and Trimethylated H3K4 Proteomic Profiling Distinguishes Acute Lymphoid Leukemia (ALL) from Acute Myeloid Leukemia (AML) and Associates wi...
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a ChildrenÍs Onc...
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability
  Steven M. Kornblau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Supercomplex Formation and Represents a New Therapeutic Target for AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all